ENDOSCOPIC TRANSORAL FUNDOPLICATION WITH MUSE FOR GASTROESOPHAGEAL REFLUX DISEASE: RESULTS OF A SINGLE CENTER STUDY

Aims:

This retrospective, chart review of prospectively collected data evaluates the clinical outcomes of patients who were treated with MUSE for GERD in a single center.

Methods:

All patient who underwent MUSE at our endoscopy center between May 2015 and June 2018 were retrospectively identified from a prospective database, collected and analyzed. The procedure was offered to patients with GERD who required and responded to pharmacological therapy. Symptoms were evaluated with a validated clinical score – GERD-HRQL score – and by monitoring the use and dosage of PPI. Clinical success was defined by ≥50% reduction of the dosage of PPI and by the GERD HRQL score (≥50% reduction compared to baseline or normalization [< 10] of the score).

Results:

Tab. 1:

Results

patients (19)	Baseline 19 patients with f/u	Last follow-up (mean 14 months) 19 patient	p
PPI usage	100%	32%	< 0.0001
median GERD-HQRL (SD)	30.3 (± 7.5)	16.3 (± 11.2)	< 0.0001
median % TRT (SD)	14.7% (± 9.81)	6.24% (± 7.05)	< 0.05
median DeMeester Score (SD)	50.17 (± 40.49)	30.34 (± 42.6)	0.17

A total of 25 patients underwent MUSE during the study period (mean age 52 [± 13], 64% males). Five patients did not complete the minimum 6-month follow-up and were excluded from analysis. One patient was lost to follow-up immediately after treatment. A median follow-up of 13.9 (6 – 36) months was available for 19 patients. At the date of the last visit, clinical success was achieved in 69% of patients (11 patients discontinued PPI and 2 patients take < 50% of the initial dosage). GERD-HRQL score was normalized or improved by ≥50% compared to baseline in 11 patients (58%). % TRT score was normal in 10/15 patients (66.6%) with post-operative pH-monitoring study.

Conclusions:

Our study confirms the safety and efficacy of the MUSE procedure for the treatment of GERD.